Hi everyone, some biotechs for you t have a look at if you are interested.
NAN
Nanosonics works in the field of infection control and the the company’s flagship product, the Trophon, used in disinfecting ultrasound probes has already become a staple standard of care in Australia with approximately 70% market penetration. Nanosonics has established a presence in Europe, the Middle East and Asia. For the past two years the company has won the NSW Premiers Export Award for the Health and Biotechnology sector.
PNV
I’ve been banging on about PNV since I first bought in around 65c and, although it’s been showing welcome signs of slowing recently, I believe it’s a winner and will be around (barring t'over) for a long time. PolyNovo Limited (ASX: PNV) is a biotechnology company which treats wounds using its polymer technology NovoSorb. It’s sales increased over 300% for the first six months and the company has signed a contract with USA Defense to supply its product to the military.'PolyNovo has been granted access to the US Department of Defence (DoD) contracts through a Defence Acquisition and Program Administration (DAPA) and Veteran’s Affairs (VA) contract. This access allows DoD facilities to purchase NovoSorb BTM for the treatment of serving military, veteran’s, and their families. DoD health facilities, anywhere in the world, will now be able to purchase NovoSorb BTM.In addition, PolyNovo has been granted access to several other United States Government contracts. The US Government will provide BTM access to Medicare/Medicaid patients under the Federal Supply Services (FSS) contract. Importantly, this enables both inpatient and outpatient treatments using BTM to be reimbursed.'
VHT
Volpara Health Technologies is a medical technology company which provides software that uses artificial intelligence imaging algorithms that assist with the early detection of breast cancer. It was also a strong performer in FY 2019, growing its annual recurring revenues materially. This strong performance allowed the company to recently raise $50 million via a placement and instutional entitlement offer. The proceeds will be used to fund the acquisition of US-based MRS Systems and further organic growth.
PAR
This one is personal having had my chronic knee pain recently diagnosed as osteoarthritis, I am looking for alternatives to surgery. The peer-reviewed papers I have read are very encouraging, Phase-3 trials commence in September. The company is using an injectable repurposed drug, pentosan polysulfate to treat chronic pain in hip and knee OA. As many of you are aware, historical drug safety data and existing manufacturing ‘know-how’ can fast-track clinical development and reduce commercialisation costs for repurposed drugs. PAR are also working in the field of reducing arthritic joint pain in Ross River fever, a debilitating mosquito-borne disease prevalent in Northern Australia and which is moving south rapidly with the effects of climate change.
I hold all four.
As always, DYOR
)
(20min delay)